Figures & data
Figure 1. Distribution of patients in this study. Fifty three patients completed 12 months administration of tadalafil, and 24 are currently continuing from 3 to 12 months of treatment. Four patients discontinued the study.
Figure 2. Change of total international prostate symptom score (IPSS) pre-treatment and after 5 mg daily tadalafil administration. Score of total IPSS was significantly decreased after tadalafil treatment.
Figure 3. Change of total overactive bladder symptoms score (OABSS) pre-treatment and after 5 mg daily tadalafil administration. Score of total OABSS was significantly decreased after tadalafil treatment.
Figure 4. Change of post-voiding residual urine (RU) pre-treatment and after 5 mg daily tadalafil administration. RU was significantly decreased after tadalafil treatment.
Figure 5. Change of max (Max) voiding flow pre-treatment and after 5 mg daily tadalafil administration. Max was significantly increased at 6 months after tadalafil treatment.
Figure 6. Change of mean (Mean) voiding flow pre-treatment and after 5 mg daily tadalafil administration. Max was also significantly increased at 6 months after tadalafil treatment.
Figure 7. Change of sexual health inventory for men (SHIM) score pre-treatment and after 5 mg daily tadalafil administration. SHIM was significantly increased after 3 months tadalafil treatment.
Figure 8. Change of brachial-ankle pulse wave velocity (baPWV) pre-treatment and after 5 mg daily tadalafil administration. BaPWV was significantly improved after 3 months tadalafil treatment.
Figure 9. Change of ankle brachial index (ABI) pre-treatment and after 5 mg daily tadalafil administration. ABI was significantly improved at 6 months after tadalafil treatment.
